This problem is evident in colorectal cancer, in which, despite the advances in therapeutic options, such as EGFR inhibitors and drug combinations using EGFR inhibitor plus VEGF inhibitor/MEK inhibitor/BRAF inhibitor, the mortality rate remains high for cancer-related deaths [22,23]. This evidence concerns the gene EGFR and cancer.